STUDY

Protopic and Elidel helped eczema more than steroids but burned and itched more

“Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.” Abędź N, Pawliczak R. Postepy Dermatologii i Alergologii. December 2019

Abędź N, Pawliczak R · Postepy Dermatologii i Alergologii · December 2019

Meta-analysis of randomized trials
The finding

Across 14 trials, topical calcineurin inhibitors caused more burning and itching than topical steroids. The pooled improvement result favored calcineurin inhibitors overall.

Type of study

Where this study sits on the evidence spectrum

Some kinds of studies are much more reliable than others. Studies further right do more to rule out chance and bias.

Weaker evidenceStronger evidence
Lab or animal studyCase reportCase seriesCohort studyRandomized trialMeta-analysis
Pooled comparisons against topical steroids. The review combined separate trials of topical calcineurin inhibitors against corticosteroids of different strengths.
At a glance

Who was studied and for how long

Trials
14
Randomized comparisons
Participants
7,376
Adults and children
Search
Through February 2018
Multiple databases and trial registers
What they did

How the study worked

Find trialsReviewers looked for randomized trials comparing topical calcineurin inhibitors with topical steroids.
Pool outcomesThey combined physician-rated improvement and reports of side effects.
Check steroid strengthThey also examined results by potency group.
What they found

The results

Physician-rated improvement

The pooled relative risk was 1.24 (95% CI 1.06 to 1.44) for improvement with calcineurin inhibitors versus steroids overall. The potency subgroup comparisons did not establish a clear advantage.

Burning and itching

Burning was more frequent with calcineurin inhibitors (relative risk 3.32, 95% CI 2.90 to 3.80), as was itching (relative risk 1.59, 95% CI 1.34 to 1.80).

The analysis compared the drug class with corticosteroids. It does not directly rank tacrolimus and pimecrolimus against each other.
How much to trust it

Strengths and limits

Strengths

  • Pooled randomized evidence
  • Compared an active steroid treatment
  • Examined both improvement and tolerability

Limits

  • Steroid potency and treatment schedules varied
  • Pooled findings do not apply to every drug and strength
  • Search ended in 2018
Moderate confidence. The pooled evidence supports a difference in local burning. The size of any efficacy advantage varies with the comparator.
What it means for you

The takeaway

Burning was more common

This review helps compare the drug classes, especially for local tolerability.

Pages that cite this study

Read more on Dermapedia

Terms in this study

Words worth knowing

Relative risk

How often an outcome happened in one group divided by how often it happened in the comparison group.

Original source

Abędź N, Pawliczak R. Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials.. Postepy Dermatol Alergol. 2019;36(6):752-759.

PMID 31998006